4.7 Article

Burden of Clostridium difficile on the Healthcare System

期刊

CLINICAL INFECTIOUS DISEASES
卷 55, 期 -, 页码 S88-S92

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis335

关键词

-

资金

  1. Optimer Pharmaceuticals, Inc.
  2. Merck
  3. Viropharma
  4. Optimer

向作者/读者索取更多资源

There are few high-quality studies of the costs of Clostridium difficile infection (CDI), and the majority of studies focus on the costs of CDI in acute-care facilities. Analysis of the best available data, from 2008, indicates that CDI may have resulted in $4.8 billion in excess costs in US acute-care facilities. Other areas of CDI-attributable excess costs that need to be investigated are costs of increased discharges to long-term care facilities, of CDI with onset in long-term care facilities, of recurrent CDI, and of additional adverse events caused by CDI.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据